XML 46 R35.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Revenue - Summary of Revenue by Sales Category (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2024 | Mar. 31, 2023
Segment Reporting Information [Line Items] |  |
Net sales | $ 9,964 | $ 9,747
Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 9,961 | 9,744
Other |  |
Segment Reporting Information [Line Items] |  |
Net sales | 3 | 3
U.S. |  |
Segment Reporting Information [Line Items] |  |
Net sales | 3,846 | 3,928
U.S. | Other |  |
Segment Reporting Information [Line Items] |  |
Net sales | 3 | 3
Int’l |  |
Segment Reporting Information [Line Items] |  |
Net sales | 6,118 | 5,819
Int’l | Other |  |
Segment Reporting Information [Line Items] |  |
Net sales | 0 | 0
Established Pharmaceutical Products | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 1,226 | 1,189
Established Pharmaceutical Products | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 0 | 0
Established Pharmaceutical Products | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 1,226 | 1,189
Nutritionals | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 2,068 | 1,967
Nutritionals | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 878 | 812
Nutritionals | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 1,190 | 1,155
Diagnostics | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 2,214 | 2,688
Diagnostics | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 931 | 1,335
Diagnostics | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 1,283 | 1,353
Medical Devices | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 4,453 | 3,900
Medical Devices | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 2,034 | 1,778
Medical Devices | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 2,419 | 2,122
Key Emerging Markets | Established Pharmaceutical Products | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 928 | 912
Key Emerging Markets | Established Pharmaceutical Products | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 0 | 0
Key Emerging Markets | Established Pharmaceutical Products | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 928 | 912
Other | Established Pharmaceutical Products | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 298 | 277
Other | Established Pharmaceutical Products | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 0 | 0
Other | Established Pharmaceutical Products | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 298 | 277
Pediatric Nutritionals | Nutritionals | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 1,009 | 924
Pediatric Nutritionals | Nutritionals | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 514 | 459
Pediatric Nutritionals | Nutritionals | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 495 | 465
Adult Nutritionals | Nutritionals | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 1,059 | 1,043
Adult Nutritionals | Nutritionals | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 364 | 353
Adult Nutritionals | Nutritionals | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 695 | 690
Core Laboratory | Diagnostics | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 1,205 | 1,182
Core Laboratory | Diagnostics | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 310 | 289
Core Laboratory | Diagnostics | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 895 | 893
Molecular | Diagnostics | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 129 | 147
Molecular | Diagnostics | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 42 | 47
Molecular | Diagnostics | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 87 | 100
Point of Care | Diagnostics | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 139 | 134
Point of Care | Diagnostics | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 98 | 93
Point of Care | Diagnostics | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 41 | 41
Rapid Diagnostics | Diagnostics | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 741 | 1,225
Rapid Diagnostics | Diagnostics | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 481 | 906
Rapid Diagnostics | Diagnostics | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 260 | 319
Rhythm Management | Medical Devices | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 562 | 527
Rhythm Management | Medical Devices | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 271 | 260
Rhythm Management | Medical Devices | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 291 | 267
Electrophysiology | Medical Devices | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 587 | 505
Electrophysiology | Medical Devices | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 269 | 238
Electrophysiology | Medical Devices | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 318 | 267
Heart Failure | Medical Devices | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 305 | 281
Heart Failure | Medical Devices | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 237 | 218
Heart Failure | Medical Devices | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 68 | 63
Vascular | Medical Devices | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 689 | 617
Vascular | Medical Devices | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 254 | 218
Vascular | Medical Devices | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 435 | 399
Structural Heart | Medical Devices | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 515 | 461
Structural Heart | Medical Devices | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 233 | 210
Structural Heart | Medical Devices | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 282 | 251
Neuromodulation | Medical Devices | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 226 | 196
Neuromodulation | Medical Devices | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 181 | 155
Neuromodulation | Medical Devices | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 45 | 41
Diabetes Care | Medical Devices | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 1,569 | 1,313
Diabetes Care | Medical Devices | U.S. | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | 589 | 479
Diabetes Care | Medical Devices | Int’l | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Net sales | $ 980 | $ 834

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=abt_EstablishedPharmaceuticalProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=abt_NutritionalProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_KeyEmergingMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_OtherEmergingMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_PediatricNutritionalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_AdultNutritionalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_CoreLaboratoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_MolecularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_PointOfCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_RapidDiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_RhythmManagementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_ElectrophysiologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_HeartFailureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_VascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_StructuralHeartMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_NeuromodulationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_DiabetesCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |